background
direct
evid
lung
cancer
risk
asian
user
angiotensinconvert
enzym
inhibitor
acei
lack
method
acei
cohort
compris
patient
age
year
first
prescript
acei
comparison
angiotensin
receptor
blocker
arb
cohort
consist
age
sexand
comorbiditymatch
patient
ratio
primari
outcom
incid
lung
cancer
evalu
use
proport
hazard
model
result
overal
incid
rate
lung
cancer
acei
arb
cohort
per
personyear
respect
acei
cohort
significantli
higher
risk
lung
cancer
arb
cohort
adjust
hazard
ratio
ahr
confid
interv
ci
durationrespons
doserespons
analys
reveal
compar
patient
receiv
acei
patient
receiv
acei
day
per
year
ahr
ci
patient
receiv
defin
daili
dose
acei
per
year
ahr
ci
significantli
higher
risk
lung
cancer
cumul
incid
lung
cancer
also
significantli
higher
acei
cohort
arb
cohort
logrank
test
p
conclus
acei
use
associ
increas
risk
lung
cancer
compar
arb
use
patient
use
arb
significantli
lower
risk
lung
cancer
nonarb
user
angiotensinconvert
enzym
inhibitor
acei
caus
vasodil
inhibit
format
angiotensin
ii
acei
compris
critic
class
antihypertens
medic
indic
heart
failur
asymptomat
left
ventricular
dysfunct
proteinuria
diabet
nephropathi
postmyocardi
infarct
safeti
concern
regard
use
acei
rais
especi
cancer
risk
hick
et
al
report
use
acei
associ
higher
risk
lung
cancer
compar
use
angiotensin
receptor
blocker
arb
howev
latest
metaanalysi
conduct
bahaj
et
al
conclud
signific
associ
exist
acei
use
develop
lung
cancer
therefor
associ
acei
lung
cancer
remain
unclear
possibl
reason
discrep
among
studi
might
baselin
bia
comorbid
insuffici
followup
confound
effect
antihypertens
medic
inadequ
select
control
cohort
nationwid
propens
scorematch
cohort
studi
reduc
baselin
bia
comorbid
antihypertens
medic
requir
addit
air
pollut
gradual
becom
global
concern
associ
increas
risk
lung
cancer
determin
hazard
effect
drug
lung
cancer
risk
realworld
set
exposur
air
pollut
consid
confound
factor
furthermor
variant
insert
delet
ace
gene
significantli
differ
asian
caucasian
popul
hick
et
al
report
associ
acei
use
lung
cancer
studi
particip
mostli
caucasian
chiang
et
al
indic
acei
arb
use
associ
allcanc
risk
taiwanes
popul
howev
result
chiang
et
al
use
establish
whether
asian
acei
user
higher
lung
cancer
risk
studi
rel
short
followup
period
cancer
latenc
consid
antihypertens
medic
specifi
lung
cancer
studi
outcom
direct
evid
lung
cancer
risk
asian
acei
user
lack
therefor
combin
data
nation
health
insur
research
databas
nhird
taiwan
air
qualiti
monitor
databas
taqmd
conduct
propens
scorematch
cohort
studi
determin
lung
cancer
risk
asian
acei
user
nation
health
insur
nhi
program
taiwan
establish
provid
univers
coverag
resid
taiwan
nhird
comprehens
databas
includ
inform
hospit
emerg
care
medic
visit
conduct
populationbas
retrospect
cohort
studi
use
data
longitudin
health
insur
databas
lhid
subset
construct
origin
registr
file
origin
claim
data
nhird
lhid
contain
data
one
million
enrolle
randomli
sampl
individu
nhird
diagnos
code
intern
classif
diseas
ninth
revis
clinic
modif
diagnost
code
nhird
ensur
encrypt
patient
inform
therefor
inform
consent
requir
studi
approv
institut
review
board
china
medic
univers
also
use
taqmd
obtain
inform
air
pollut
combin
stratifi
lhid
taqmd
data
link
residenti
area
enrolle
nearbi
air
qualiti
monitor
station
enrol
patient
age
older
year
januari
decemb
divid
two
cohort
acei
cohort
arb
cohort
acei
cohort
consist
patient
prescrib
acei
least
day
wherea
arb
cohort
consist
patient
prescrib
arb
least
day
date
first
acei
arb
use
studi
period
defin
index
date
patient
cancer
code
studi
period
histori
lung
cancer
index
date
exclud
studi
control
confound
effect
perform
propens
score
match
acei
arb
cohort
follow
covari
age
sex
monthli
incom
urban
level
diagnosi
hypertens
diabet
tuberculosi
alcoholrel
diseas
chronic
obstruct
pulmonari
diseas
copd
chronic
liver
diseas
hyperlipidemia
asthma
stroke
coronari
arteri
diseas
rheumatolog
diseas
use
medic
includ
potassiumspar
diuret
thiazid
loop
diuret
calcium
channel
blocker
air
pollut
air
pollut
concentr
refer
daili
averag
concentr
lung
cancer
code
defin
endpoint
studi
particip
followedup
index
date
date
lung
cancer
diagnosi
withdraw
nhi
program
decemb
whichev
occur
first
estim
propens
score
logist
regress
model
use
acei
arb
use
statu
regress
baselin
characterist
list
tabl
distribut
demograph
characterist
clinic
comorbid
statu
compar
acei
arb
cohort
differ
examin
use
student
ttest
continu
variabl
chisquar
test
categor
variabl
age
daili
averag
daili
averag
ppb
daili
averag
distribut
gaussiannorm
distribut
therefor
use
nonparametr
statist
mannwhitney
u
test
test
age
daili
averag
daili
averag
ppb
daili
averag
differ
cohort
classifi
monthli
incom
urban
three
four
level
respect
cox
proport
hazard
regress
use
estim
adjust
hazard
ratio
ahr
confid
interv
ci
lung
cancer
occurr
result
analyz
accord
variou
doserespons
categori
covari
list
tabl
includ
multivari
cox
proport
hazard
regress
model
analyz
doserespons
effect
among
patient
use
acei
arb
calcul
averag
day
averag
dose
averag
ddd
defin
daili
dosag
acei
arb
per
year
divid
total
use
day
total
prescrib
dose
followup
period
classifi
patient
two
subgroup
median
measur
cumul
incid
lung
cancer
acei
arb
cohort
use
kaplanmei
method
assess
curv
differ
use
logrank
test
sa
version
sa
institut
inc
cari
nc
usa
use
data
analys
twosid
signific
level
set
p
select
patient
receiv
acei
treatment
patient
receiv
arb
treatment
sex
age
distribut
similar
two
cohort
mean
age
cohort
approxim
year
signific
differ
observ
monthli
incom
urban
level
two
cohort
p
arb
cohort
like
coronari
arteri
diseas
p
regard
distribut
air
pollut
daili
averag
concentr
significantli
higher
acei
cohort
arb
cohort
p
tabl
mean
followup
time
year
year
arb
acei
cohort
respect
end
studi
period
overal
incid
rate
lung
cancer
arb
acei
cohort
per
personyear
respect
multivari
cox
proport
hazard
regress
model
adjust
age
sex
comorbid
medic
air
pollut
significantli
higher
risk
lung
cancer
observ
acei
cohort
arb
cohort
ahr
ci
tabl
durationrespons
doserespons
analys
reveal
compar
patient
receiv
acei
treatment
patient
receiv
acei
treatment
day
per
year
ahr
ci
patient
receiv
mg
acei
per
year
ahr
ci
patient
receiv
defin
daili
dose
ddd
acei
per
year
ahr
ci
significantli
higher
risk
lung
cancer
compar
patient
receiv
arb
treatment
patient
receiv
arb
treatment
fewer
day
per
year
ahr
ci
patient
receiv
mg
arb
per
year
ahr
ci
patient
receiv
fewer
ddd
arb
per
year
ahr
ci
significantli
lower
risk
lung
cancer
tabl
kaplanmei
analysi
cumul
incid
lung
cancer
significantli
higher
acei
cohort
arb
cohort
logrank
test
p
figur
kaplanmei
analysi
cumul
incid
lung
cancer
significantli
higher
acei
cohort
arb
cohort
logrank
test
p
figur
similar
find
hick
et
al
studi
reveal
acei
user
higher
risk
lung
cancer
compar
arb
user
analysi
reveal
acei
user
higher
risk
lung
cancer
medic
use
day
accumul
dosag
acei
mg
respect
patient
receiv
arb
accumul
dosag
mg
lower
risk
lung
cancer
addit
caus
vasodilat
circul
system
acei
also
activ
lung
ace
abund
use
acei
could
result
increas
level
bradykinin
lung
normal
degrad
acei
may
mediat
sensit
airway
enhanc
cough
reflex
furthermor
bradykinin
associ
regul
neointim
format
mitogenesi
mitogenactiv
protein
kinas
pathway
chee
et
al
indic
bradykinin
receptor
highli
express
cytoplasm
type
lung
tumor
would
mediat
proangiogen
properti
cancer
migrat
invas
metastasi
addit
acei
use
could
caus
accumul
substanc
p
lung
esteban
et
al
report
activ
receptor
substanc
p
one
mechan
link
mitogenesi
cancer
promot
progress
munoz
et
al
indic
substanc
p
may
induc
prolifer
tumor
cell
endotheli
cell
thu
stimul
angiogenesi
therefor
increas
level
substanc
p
bradykinin
lung
may
mechan
acei
user
higher
risk
lung
cancer
durationrespons
doserespons
relationship
acei
use
lung
cancer
strengthen
clinic
find
present
studi
observ
arb
user
significantli
lower
risk
lung
cancer
nonarb
user
metaanalysi
zhang
et
al
also
demonstr
arb
associ
significantli
lower
lung
cancer
risk
cohort
studi
conduct
chang
et
al
huang
et
al
also
reveal
arb
use
associ
decreas
risk
lung
cancer
bhaskaran
et
al
observ
decreas
risk
lung
cancer
arb
user
studi
report
angiotensin
ii
receptor
receptor
receptor
involv
enhanc
tissu
vascular
endotheli
growth
factor
protein
level
angiogenesi
tumor
growth
similar
find
hick
et
al
studi
reveal
acei
user
higher
risk
lung
cancer
compar
arb
user
analysi
reveal
acei
user
higher
risk
lung
cancer
medic
use
day
accumul
dosag
acei
mg
respect
patient
receiv
arb
accumul
dosag
mg
lower
risk
lung
cancer
addit
caus
vasodilat
circul
system
acei
also
activ
lung
ace
abund
use
acei
could
result
increas
level
bradykinin
lung
normal
degrad
acei
may
mediat
sensit
airway
enhanc
cough
reflex
furthermor
bradykinin
associ
regul
neointim
format
mitogenesi
mitogenactiv
protein
kinas
pathway
chee
et
al
indic
bradykinin
receptor
highli
express
cytoplasm
type
lung
tumor
would
mediat
proangiogen
properti
cancer
migrat
invas
metastasi
addit
acei
use
could
caus
accumul
substanc
p
lung
esteban
et
al
report
activ
receptor
substanc
p
one
mechan
link
mitogenesi
cancer
promot
progress
munoz
et
al
indic
substanc
p
may
induc
prolifer
tumor
cell
endotheli
cell
thu
stimul
angiogenesi
therefor
increas
level
substanc
p
bradykinin
lung
may
mechan
acei
user
higher
risk
lung
cancer
durationrespons
doserespons
relationship
acei
use
lung
cancer
strengthen
clinic
find
present
studi
observ
arb
user
significantli
lower
risk
lung
cancer
nonarb
user
metaanalysi
zhang
et
al
also
demonstr
arb
associ
significantli
lower
lung
cancer
risk
cohort
studi
conduct
chang
et
al
huang
et
al
also
reveal
arb
use
associ
decreas
risk
lung
cancer
bhaskaran
et
al
observ
decreas
risk
lung
cancer
arb
user
studi
report
angiotensin
ii
receptor
receptor
receptor
involv
enhanc
tissu
vascular
endotheli
growth
factor
protein
level
angiogenesi
tumor
growth
addit
receptor
abundantli
express
malign
neoplasm
includ
variou
type
lung
cancer
fujita
et
al
reveal
block
angiotensin
ii
receptor
could
reduc
tumor
growth
metastasi
suganuma
et
al
fujimoto
et
al
report
blockad
therapi
angiotensin
ii
receptor
could
suppress
metastasi
human
ovarian
cancer
pancreat
cancer
vitro
gong
et
al
indic
block
angiotensin
ii
type
receptor
could
induc
apoptot
cell
death
human
pancreat
cancer
cell
vitro
aforement
find
indic
potenti
biolog
mechan
find
arb
user
lower
risk
lung
cancer
blockad
reninangiotensin
system
ra
wellknown
benefici
preserv
heart
kidney
function
heart
failur
postmyocardi
infarct
kidney
diseas
therefor
would
imposs
complet
omit
rasblock
medic
patient
heart
kidney
diseas
therefor
employ
studi
design
similar
hick
et
al
compar
lung
cancer
risk
acei
arb
cohort
compar
lung
cancer
risk
acei
nonacei
user
well
arb
user
nonarb
user
result
directli
answer
realworld
clinic
question
provid
suffici
inform
decisionmak
select
ra
blocker
sever
limit
current
studi
note
first
inform
smoke
habit
includ
intens
durat
physic
exercis
person
exposur
secondhand
smoke
asbesto
beryllium
cadmium
silica
inhal
carcinogen
bodi
mass
index
unavail
nhird
sinc
lung
cancer
end
point
paper
lack
inform
smoke
habit
exposur
carcinogen
lung
cancer
rais
concern
baselin
bia
howev
attempt
use
copd
proxi
smoke
habitat
also
consid
analyz
asthma
tuberculosi
level
air
pollut
possibl
baselin
bia
might
minim
second
adjust
medic
visit
chest
examin
frequenc
includ
chest
xray
comput
tomographi
magnet
reson
imag
ultrasonographi
therefor
surveil
bia
might
present
acei
user
symptom
dri
cough
undergo
chest
examin
third
detail
patholog
report
small
cell
nonsmal
cell
lung
cancer
stage
lung
cancer
unavail
nhird
therefor
analysi
associ
acei
use
subgroup
lung
cancer
could
perform
studi
fourth
mobil
particip
could
certain
therefor
select
residenti
area
featur
would
repres
real
exposur
condit
particip
final
medic
adher
could
fulli
ascertain
studi
studi
sever
strength
first
use
propens
score
match
mitig
baselin
bia
acei
arb
cohort
divers
popul
differ
reason
acei
use
propens
score
match
could
minim
baselin
bia
underli
diseas
acei
arb
cohort
addit
match
comorbid
also
match
type
antihypertens
medic
acei
arb
cohort
therebi
baselin
bia
antihypertens
medic
minim
second
consid
air
pollut
recogn
signific
risk
factor
lung
cancer
accord
literatur
review
first
studi
consid
air
pollut
covari
investig
associ
acei
lung
cancer
third
studi
enrol
start
use
acei
arb
index
date
use
acei
arb
index
date
switch
acei
arb
exclud
studi
therebi
bia
consider
minim
fourth
nhi
cover
popul
taiwan
contain
decad
data
thu
best
knowledg
mean
followup
durat
nationwid
populationbas
studi
longest
among
similar
studi
acei
lung
cancer
long
followup
enabl
repres
analysi
relationship
acei
dosag
durat
lung
cancer
risk
furthermor
hick
et
al
specul
increas
lung
cancer
risk
observ
acei
user
might
due
protect
effect
arb
lung
cancer
studi
clearli
demonstr
protect
effect
arb
lung
cancer
potenti
acei
caus
lung
cancer
separ
compar
acei
user
nonacei
user
arb
user
nonarb
user
conclus
acei
user
higher
risk
lung
cancer
arb
user
taiwan
dosagerespons
durationrespons
relationship
exist
acei
use
lung
cancer
risk
